Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of tenofovir alafenamide withdrawal timing to prevent mother-to-child transmission of hepatitis B virus
ChiCTR1900023803Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir alafenamide in hepatitis B (HBV) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Safety of tenofovir alafenamide for mothers and infants, Successful rate of prevention for mother-to-child transmission of hepatitis B virus and 1 more. Started Jun 2019; status: recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR1900023803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023803.